Archives of Gynecology and Obstetrics

, Volume 290, Issue 3, pp 425–434

Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey

  • Giuseppe Grosso
  • Diego Rossetti
  • Federico Coccolini
  • Giorgio Bogani
  • Luca Ansaloni
  • Luigi Frigerio
Review

DOI: 10.1007/s00404-014-3252-2

Cite this article as:
Grosso, G., Rossetti, D., Coccolini, F. et al. Arch Gynecol Obstet (2014) 290: 425. doi:10.1007/s00404-014-3252-2

Abstract

Introduction

Intraperitoneal chemotherapy preceded by cytoreductive surgery should be the standard of care in the treatment of advanced epithelial ovarian cancer. This combination has been extensively examined in both the clinical and preclinical settings with favourable oncologic outcomes. Unfortunately, despite the existence of these evidence-based data, this management strategy remains underutilised.

Materials and methods

We review and discuss the role of intraperitoneal chemotherapy with particular emphasis about the pharmacokinetics and pharmacodynamics aspects, the mode of administration, the reported side effects, the compliance of the patients and the clinical ongoing studies.

Conclusions

Further studies investigating the pharmacokinetics and pharmacodynamics aspect of IP route may help to reduce toxicity pending more effective treatments.

Keywords

Intraperitoneal chemotherapy Advanced ovarian cancer Cytoreductive surgery HIPEC 

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Giuseppe Grosso
    • 1
  • Diego Rossetti
    • 1
  • Federico Coccolini
    • 2
  • Giorgio Bogani
    • 3
  • Luca Ansaloni
    • 2
  • Luigi Frigerio
    • 1
  1. 1.Department of Gynecology and ObstetricsPapa Giovanni XXIII HospitalBergamoItaly
  2. 2.Department of SurgeryPapa Giovanni XXIII HospitalBergamoItaly
  3. 3.Department of Obstetrics and GynecologyUniversity of Insubria, Del Ponte HospitalVareseItaly

Personalised recommendations